Selective thyromimetics for atherosclerosis and dyslipidaemia: another old target making progress

Bibliography

• Suckling KE, MacPhee CH. Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque. Expert Opin Ther Targets 2002;6:309-14
   PubMedGoogle Scholar
• Steinberg D. An interpretive history of the cholesterol controversy: part I [Review]. J Lipid Res 2004;45:1583-93
   PubMed Web of Science ®Google Scholar
• Steinberg D. An interpretive history of the cholesterol controversy. Part II: the early evidence linking hypercholesterolemia to coronary disease in humans [Review]. J Lipid Res 2005;46:179-90
   PubMed Web of Science ®Google Scholar
• Duntas LH. Thyroid disease and lipids. Thyroid 2002;12:287-93
   PubMed Web of Science ®Google Scholar
• Kritchevsky D. The action of thyromimetic compounds on experimental atherosclerosis in rabbits and on cholesterol metabolism in rats. Rev Atheroscler 1963;26:81-92
   Google Scholar
• Brenta G, Danzi S, Klein I. Potential therapeutic applications of thyroid hormone analogs. Nat Clin Pract Endocrinol Metab 2007;3:632-40
   PubMedGoogle Scholar
• Underwood AH, Emmett JC, Ellis D, et al. A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature 1986;324:425-9
   PubMed Web of Science ®Google Scholar
• Barlow JW, Raggatt LE, Lim CF, et al. The thyroid hormone analogue SKF-94901 and iodothyronine binding sites in mammalian tissues: differences in cytoplasmic binding between liver and heart. Acta Endocrinol (Copenh) 1991;124:37-44
   PubMedGoogle Scholar
• Ichikawa K, Miyamoto T, Kakizawa T, et al. Mechanism of liver-selective thyromimetic activity of SK&F L-94901: evidence for the presence of a cell-type-specific nuclear iodothyronine transport process. J Endocrinol 2000;165:391-7
   PubMed Web of Science ®Google Scholar
• Ness GC, Lopez D, Chambers CM, et al. Effects of l-triiodothyronine and the thyromimetic L-94901 on serum-lipoprotein levels and hepatic low-density-lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme-A reductase, and apoA-1 gene-expression. Biochem Pharmacol 1998;56:121-9
   PubMed Web of Science ®Google Scholar
• Kuipers F, Stroeve JH, Caron S, Staels B. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control. Curr Opin Lipidol 2007;18:289-97
   PubMed Web of Science ®Google Scholar
• Geyeregger R, Zeyda M, Stulnig TM. Liver X receptors in cardiovascular and metabolic disease. Cell Mol Life Sci 2006;63:524-39
   PubMed Web of Science ®Google Scholar
• Gervois P, Fruchart J-C, Staels B. Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab 2007;3:145-56
   PubMedGoogle Scholar
• Taylor AH, Stephan ZF, Steele RE, Wong NC. Beneficial effects of a novel thyromimetic on lipoprotein metabolism. Mol Pharmacol 1997;52:542-7
   PubMed Web of Science ®Google Scholar
• Wada Y, Matsubara S, Dufresne J, et al. Effects of a thyromimetic on apolipoprotein B-100 in rats. J Mol Endocrinol 2000;25:299-308
   PubMed Web of Science ®Google Scholar
• Trost SU, Swanson E, Gloss B, et al. The thyroid hormone receptor-β-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 2000;141:3057-64
   PubMed Web of Science ®Google Scholar
• Garg N, Li YL, Garcia Collazo AM, et al. Thyroid receptor ligands. Part 8: thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141. Bioorg Med Chem Lett 2007;17:4131-4
   PubMed Web of Science ®Google Scholar
• Suckling KE. The ideal model in atherosclerosis and dyslipidaemia: does it exist? Expert Opin Drug Discov 2007;1:507-11
   Web of Science ®Google Scholar
• Fugier C, Tousaint JJ, Prieur X, et al. The lipoprotein lipase inhibitor ANGPTL3 is negatively regulated by thyroid hormone. J Biol Chem 2006;281:11553-9
   PubMed Web of Science ®Google Scholar
• Prieur X, Huby T, Coste H, et al. Thyroid hormone regulates the hypotriglyceridemic gene apoA5. J Biol Chem 2005;280:27533-43
   PubMed Web of Science ®Google Scholar
• Drover VAB, Wong NCW, Agellon LB. A distinct thyroid hormone response element mediates repression of the human cholesterol 7 alpha-hydroxylase (CYP7A1) gene promoter. Mol Endocrinol 2002;16:14-23
   PubMed Web of Science ®Google Scholar
• Kawai K, Sasaki S, Morita H, et al. Unliganded thyroid hormone receptor-beta 1 represses liver X receptor alpha/oxysterol-dependent transactivation. Endocrinology 2004;145:5515-24
   PubMed Web of Science ®Google Scholar
• Huuskonen J, Vishnu M, Pullinger CR, et al. Regulation of ATP-binding cassette transporter A1 transcription by thyroid hormone receptor. Biochemistry 2004;43:1626-32
   PubMed Web of Science ®Google Scholar
• Webb P. Selective activators of thyroid hormone receptors. Expert Opin Invest Drugs 2004;13:489-500
   PubMed Web of Science ®Google Scholar
• Malm J. Therapeutic thyroid hormone ligand patents 1998 – 2003. Expert Opin Ther Patents 2004;14:1169-83
   Web of Science ®Google Scholar
• Grover GJ, Mellstrom K, Ye L, et al. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci USA 2003;100:10067-72
   PubMed Web of Science ®Google Scholar
• Berkenstam A, Kristensen J, Mellstrom K, et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 2007;105:663-7
   PubMed Web of Science ®Google Scholar
• Suckling K. The continuing complexities of high-density lipoprotein metabolism in drug discovery and development. Expert Opin Ther Targets 2007;11:1133-6
   PubMed Web of Science ®Google Scholar
• Suckling K. ENHANCE: unusual publication of trial data raise questions beyond ezetimibe. Expert Opin Pharmacother 2008;9(7):1067-70
   PubMed Web of Science ®Google Scholar